Prothena names Gene Kinney as president, CEO and director
Dr. Kinney has also been appointed to Prothena's Board of Directors. The appointments come following the passing of Prothena's Co-founder, President and CEO, Dr. Dale B. Schenk on September 30, 2016.
Dr. Kinney worked with Dr. Schenk since 2009, first at Elan and then at Prothena when the Company spun out of Elan in 2012 as a preclinical stage company.
As a founding member of Prothena's leadership team, Dr. Kinney was Head of Research and Development and Chief Scientific Officer and led the team responsible for advancing a robust pipeline into late-stage clinical development as well as generating novel antibody targets in discovery.
Dr. Kinney was recently named Chief Operating Officer of Prothena and had been leading the Company since Dr. Schenk began a medical leave of absence.
Prior to joining Prothena, in positions of increasing scope, Dr. Kinney has held responsibility for overseeing portfolio strategy, leading R&D teams, and supporting commercial product launches.
He was Senior Vice President of Pharmacological Sciences at Elan Pharmaceuticals, Inc. and held several senior R&D positions not only at Elan, but also Janssen Alzheimer Immunotherapy R&D, Merck Research Laboratories and Bristol-Myers Squibb, and was an Assistant Professor at the Emory University School of Medicine.
Dr. Kinney earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. ■
LATEST MOVES FROM Ireland
- Stellwagen Group appoints two executives
- Allegion appoints Nicole Parent Haughey to board
- Johnson Controls says George Oliver will become chairman
- Fly Leasing appoints Julie Ruehl as CFO
- Venn Life Sciences appoints Christian Bernard Milla as COO
More inside POST
Valeant earned $1.05 per share in Q2 Earnings